Real world evidence (RWE) is playing an increasingly vital role in health technology assessment (HTA), the EU Joint Clinical Assessment (JCA), and payer decision-making worldwide. A key challenge emerging is how to use evidence generated in one jurisdiction to inform decisions in another—a concept known as evidence transportability. As pharmaceutical manufacturers seek efficient, evidence generation solutions that overcome limitations of data sources in the target jurisdiction without costly duplication of studies across regions, evidence transportability is gaining traction as a pragmatic approach.
Download our paper to explore the growing need for evidence transportability, common use cases, the challenges in applying non-local data, and learn more about our structured framework to assess and enable evidence transportability effectively.
Lumanity guides companies through this complex landscape, leveraging unique data access and methodological know-how. Contact us to optimize your evidence transportability strategies.
"*" indicates required fields
